A Phase 3 interventional study of Pembrolizumab and Carboplatin in Triple Negative Breast Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 193 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
How we know · 16 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms — 17 open to participants now, 27 under way, 4 of them phase 3. pembrolizumab · Triple Negative Breast Neoplasms.
Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, this one is the 4th largest by enrollment, is one of 9 that started in 2017, is one of 7 in phase 3, and was the 15th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →17 of the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
UNICANCER · Sites in Belgium, France
Ages 18+
UNICANCER · Sites in France, Spain
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 7
First in 2010; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,174 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 52 across the 49 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc: 3 open now, 3 under way, 3 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Triple Negative Breast Neoplasms studies by the year they started, since 2014.
9 of the studies testing pembrolizumab in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT04683679Memorial Sloan Kettering Cancer CenterA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | 2027-01 |
| NCT04468061Dana-Farber Cancer InstituteSacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | 2027-04-01 |
| NCT06407310Tel Aviv Medical CenterNeoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | 2027-04-01 |
| NCT04427293University of Illinois at ChicagoPreoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 49 studies testing pembrolizumab in Triple Negative Breast Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 17 in Triple Negative Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).
After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant study treatment. After definitive surgery, each participant will receive adjuvant study treatment (Pembrolizumab OR Placebo) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence.
The primary study hypothesis is that pembrolizumab is superior to placebo, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR) and/or Event-free Survival (EFS), in participants with locally advanced TNBC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has previously untreated locally advanced non- (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee of Cancer (AJCC) staging criteria for breast cancer as assessed by the investigator based on radiological and/or clinical assessment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 200 mg pembrolizumab every 3 weeks (Q3W) + 80 mg/m\^2 paclitaxel weekly + carboplatin (Area Under the Curve \[AUC\]1.5 weekly or AUC5 Q3W) x 4 cycles, followed by 200 mg pembrolizumab Q3W + (60 mg/m\^2 doxorubicin OR 90 mg/m\^2 epirubicin) + 600 mg/m\^2 cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of 200 mg pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Participants receive placebo (normal saline solution) Q3W + 80 mg/m\^2 paclitaxel weekly + carboplatin (AUC1.5 weekly or AUC5 Q3W) x 4 cycles, followed by placebo + (60 mg/m\^2 doxorubicin OR 90 mg/m\^2 epirubicin) + 600 mg/m\^2 cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
Drug: Carboplatin · Drug: Paclitaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Placebo · Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
Also known as: MK-3475, KEYTRUDA®
On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
Also known as: PARAPLATIN®
On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
Also known as: TAXOL®
On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
Also known as: ADRIAMYCIN®
On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
Also known as: ELLENCE®
On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
Also known as: CYTOXAN®
normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgrastim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
Also known as: NEUPOGEN®, NEULASTA®
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants
pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
Event-free Survival (EFS) in All Participants
EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.
Time frame: Up to approximately 102 months
Overall Survival (OS) in All Participants
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 102 months
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants
pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1)
pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
pCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
EFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.
Time frame: Up to approximately 102 months
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants
pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
Time frame: Up to approximately 27-30 weeks
Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 102 months
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who experienced an AE was reported. AEs were reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable adverse event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).
Time frame: Up to approximately 107 weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who discontinued study treatment due to an AE was reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).
Time frame: Up to approximately 95 weeks
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants
The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Change From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Change From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants
The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
Change From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1)
The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
Time frame: Neoadjuvant: Baseline and Week 21; Adjuvant: Baseline and Week 24
| Milestone | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Started | 784 | 390 |
| Treated in the neoadjuvant phase | 783 | 389 |
| Received surgery | 768 | 381 |
| Treated in the adjuvant phase | 588 | 331 |
| Completed | 0 | 0 |
| Not completed | 784 | 390 |
| Withdrew: Withdrawal by subject | 12 | 8 |
| Withdrew: Sponsor decision | 652 | 295 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 119 | 87 |
OS was defined as the time from randomization to death due to any cause.
| Months | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival (OS) in All Participants | NA (NA to NA) | NA (NA to NA) |
pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in All Participants | 58.7 (54.9 to 62.5) | 49.5 (44.1 to 55.1) |
pCR rate (ypT0 ypN0) was defined as the percentage of participants without residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| pCR Rate Using an Alternative Definition, ypT0 ypN0 (i.e., no Invasive or Noninvasive Residual in Breast or Nodes) at the Time of Definitive Surgery in Participants With Programmed Death Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS] ≥ 1) | 62.0 (57.8 to 66.0) | 52.4 (46.3 to 58.5) |
pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| pCR Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | 67.1 (63.1 to 71.0) | 58.3 (52.2 to 64.2) |
EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.
| Months | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| EFS in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | NA (NA to NA) | NA (NA to NA) |
pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in All Participants | 66.8 (63.1 to 70.4) | 57.4 (51.8 to 62.7) |
pCR rate (ypT0/Tis) was defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| pCR Rate Using an Alternative Definition, ypT0/Tis (i.e., Absence of Invasive Cancer in the Breast Irrespective of Ductal Carcinoma in Situ or Nodal Involvement) at the Time of Definitive Surgery in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | 70.0 (66.0 to 73.8) | 61.3 (55.2 to 67.1) |
OS was defined as the time from randomization to death due to any cause.
| Months | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | NA (NA to NA) | NA (NA to NA) |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who experienced an AE was reported. AEs were reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable adverse event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).
| Participants | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) | Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases) | Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases) |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 777 | 389 | 541 | 294 | 777 | 389 |
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product which does not have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the product or procedure. Any worsening (clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the Sponsor's product was an AE. The number of participants who discontinued study treatment due to an AE was reported for the neoadjuvant phase, adjuvant phase, and combined phases. Each participant is counted a single time for each applicable event per treatment phase (i.e. Neoadjuvant, Adjuvant, Combined).
| Participants | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) | Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases) | Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases) |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 204 | 53 | 32 | 8 | 233 | 60 |
The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
| Score on a scale | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) |
|---|---|---|---|---|
| Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score in All Participants | -11.24 (-12.82 to -9.66) | -10.20 (-12.30 to -8.10) | 2.47 (1.05 to 3.88) | 2.88 (1.05 to 4.71) |
The EORTC QLQ-C30 assesses quality of life in cancer patients and includes 30 questions: 1 global scale; 5 functional scales (physical, role, cognitive, emotional, social); 3 symptom scales (fatigue, nausea, pain); 6 symptoms (dyspnea, appetite loss, insomnia, constipation, diarrhea); \& financial impact. Items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scale scores are standardized to 0-100. Higher global and functional scores indicate better functioning, while higher symptom scores indicate worse symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
| Score on a scale | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) |
|---|---|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | -11.63 (-13.35 to -9.91) | -10.95 (-13.25 to -8.64) | 1.88 (0.31 to 3.46) | 2.49 (0.47 to 4.51) |
The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
| Score on a scale | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) |
|---|---|---|---|---|
| Change From Baseline in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Breast Symptoms Score in All Participants | -9.92 (-11.34 to -8.49) | -9.78 (-11.53 to -8.03) | -5.73 (-7.32 to -4.15) | -6.02 (-8.04 to -4.01) |
pCR rate (ypT0/Tis ypN0) was defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.
| Percentage of Participants | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants | 64.0 (60.2 to 67.6) | 54.7 (49.1 to 60.1) |
EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, as assessed by Investigator, or death due to any cause.
| Months | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy |
|---|---|---|
| Event-free Survival (EFS) in All Participants | NA (NA to NA) | NA (NA to NA) |
The EORTC QLQ-BR23 is a breast-specific module of the EORTC QLQ. It includes 23 items composed of 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and 4 symptom scales (systemic therapy side effects, breast symptoms, arm symptoms and upset by hair loss). Individual responses are given on a 4-point scale (1=Not at All to 4=Very Much). Scores for each scale are standardized into a range of 0 to 100. A higher score on the symptom scale shows a higher ("worse") level of symptoms. Results were presented separately for the neoadjuvant and adjuvant phases, with side-by-side review of phase-specific outputs. A combined phase analysis was not presented because the phases represent distinct clinical settings with different baselines; the adjuvant population is a subset of the neoadjuvant population; and pooling data would introduce substantial missingness, limiting clinical interpretability of the results.
| Score on a scale | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) |
|---|---|---|---|---|
| Change From Baseline in EORTC QLQ-BR23 Breast Symptoms Score in Participants With PD-L1 Positive Tumors (CPS ≥ 1) | -9.43 (-11.03 to -7.84) | -9.19 (-11.17 to -7.21) | -5.47 (-7.26 to -3.67) | -6.27 (-8.53 to -4.00) |
Collected over Up to approximately 102 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | 9/783 (1.1%) | 315/783 (40.2%) | 774/783 (98.9%) |
| Placebo + Chemotherapy (Neoadjuvant Phase) | 2/389 (0.5%) | 101/389 (26%) | 389/389 (100%) |
| Pembrolizumab (Adjuvant Phase) | 7/588 (1.2%) | 41/588 (7%) | 482/588 (82%) |
| Placebo (Adjuvant Phase) | 6/331 (1.8%) | 14/331 (4.2%) | 268/331 (81%) |
| Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases) | 120/784 (15.3%) | 341/783 (43.6%) | 774/783 (98.9%) |
| Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases) | 90/390 (23.1%) | 111/389 (28.5%) | 389/389 (100%) |
| Event | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) | Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases) | Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases) |
|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 119/783 | 47/389 | 0/588 | 0/331 | 119/783 | 47/389 |
| PyrexiaGeneral disorders | 29/783 | 2/389 | 0/588 | 0/331 | 29/783 | 2/389 |
| AnaemiaBlood and lymphatic system disorders | 20/783 | 9/389 | 0/588 | 0/331 | 20/783 | 9/389 |
| PneumoniaInfections and infestations | 4/783 | 6/389 | 3/588 | 2/331 | 7/783 | 8/389 |
| NeutropeniaBlood and lymphatic system disorders | 12/783 | 1/389 | 0/588 | 0/331 | 12/783 | 1/389 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/783 | 2/389 | 2/588 | 0/331 | 12/783 | 2/389 |
| PancytopeniaBlood and lymphatic system disorders | 11/783 | 4/389 | 0/588 | 0/331 | 11/783 | 4/389 |
| Postoperative wound infectionInfections and infestations | 3/783 | 4/389 | 0/588 | 1/331 | 3/783 | 5/389 |
| SepsisInfections and infestations | 7/783 | 4/389 | 2/588 | 0/331 | 9/783 | 4/389 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/783 | 3/389 | 4/588 | 1/331 | 9/783 | 4/389 |
| Event | Pembrolizumab + Chemotherapy (Neoadjuvant Phase) | Placebo + Chemotherapy (Neoadjuvant Phase) | Pembrolizumab (Adjuvant Phase) | Placebo (Adjuvant Phase) | Pembrolizumab + Chemotherapy / Pembrolizumab (Neoadjuvant and Adjuvant Combined Phases) | Placebo + Chemotherapy / Placebo (Neoadjuvant and Adjuvant Combined Phases) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 512/783 | 254/389 | 40/588 | 26/331 | 522/783 | 256/389 |
| AlopeciaSkin and subcutaneous tissue disorders | 476/783 | 226/389 | 4/588 | 0/331 | 477/783 | 226/389 |
| AnaemiaBlood and lymphatic system disorders | 448/783 | 222/389 | 34/588 | 16/331 | 452/783 | 223/389 |
| NeutropeniaBlood and lymphatic system disorders | 370/783 | 186/389 | 38/588 | 26/331 | 371/783 | 189/389 |
| FatigueGeneral disorders | 346/783 | 156/389 | 50/588 | 31/331 | 366/783 | 168/389 |
| ConstipationGastrointestinal disorders | 323/783 | 137/389 | 32/588 | 19/331 | 328/783 | 150/389 |
| DiarrhoeaGastrointestinal disorders | 293/783 | 119/389 | 52/588 | 29/331 | 316/783 | 133/389 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 137/783 | 75/389 | 110/588 | 66/331 | 228/783 | 122/389 |
| VomitingGastrointestinal disorders | 233/783 | 104/389 | 27/588 | 9/331 | 243/783 | 107/389 |
| Alanine aminotransferase increasedInvestigations | 228/783 | 104/389 | 31/588 | 15/331 | 236/783 | 108/389 |
The baseline analysis population consisted of all randomized participants.
| Age, Continuous(Years) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Mean | 49.2 ± 11.8 | 49.1 ± 11.9 | 49.1 ± 11.8 |
| Sex: Female, Male(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Female | 783 | 390 | 1173 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 85 | 39 | 124 |
| Not Hispanic or Latino | 616 | 307 | 923 |
| Unknown or Not Reported | 83 | 44 | 127 |
| Race (NIH/OMB)(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 14 | 7 | 21 |
| Asian | 149 | 89 | 238 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 38 | 15 | 53 |
| White | 504 | 242 | 746 |
| More than one race | 13 | 6 | 19 |
| Unknown or Not Reported | 65 | 31 | 96 |
| Nodal Status(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Positive | 405 | 200 | 605 |
| Negative | 379 | 190 | 569 |
| Tumor Size(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| T1/T2 | 580 | 290 | 870 |
| T3/T4 | 204 | 100 | 304 |
| Choice of Carboplatin(Participants) | Pembrolizumab + Chemotherapy | Placebo + Chemotherapy | Total |
|---|---|---|---|
| Every 3 Weeks (Q3W) | 335 | 167 | 502 |
| Weekly | 449 | 223 | 672 |
Showing the first 100 of 193 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2017 to primary completion in Oct 2025, 103 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's 103 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab
Triple Negative Breast Neoplasms →